Publication Name	World Journal of Clinical Cases
Manuscript ID	71264
Country	Aruba

Received	2021-09-01 16:46
Peer-Review Started	2021-09-01 16:50
To Make the First Decision
Return for Revision	2021-11-08 09:49
Revised	2021-11-21 08:30
Second Decision	2022-02-08 05:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-02-10 10:37
Articles in Press	2022-02-10 10:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-02-19 13:18
Publish the Manuscript Online	2022-03-11 00:39

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Michael Au, Nikola Mitrev, Rupert W Leong and Viraj Kariyawasam
ORCID	Author(s) ORCID Number Michael Au http://orcid.org/0000-0002-5015-701X Nikola Mitrev http://orcid.org/0000-0001-7771-5248 Rupert W Leong http://orcid.org/0000-0001-5944-3488 Viraj Kariyawasam http://orcid.org/0000-0003-2623-1336
Funding Agency and Grant Number
Corresponding Author	Michael Au, MBBS, Doctor, Department of Gastroenterology and Hepatology, Blacktown and Mt Druitt Hospitals, Western Sydney Local Health District, Blacktown and Mt Druitt Hospitals, Blacktown and Mt Druitt Hospitals, Sydney 2148, New South Wales, Australia. michael.au@my.jcu.edu.au
Key Words	Dual biologic therapy; Combination; Immunosuppression; Safety; Autoimmune; Case report
Core Tip	This paper describes the use of two biologics for the treatment of Crohn's disease and multiple sclerosis. Only a few papers have reported the safety and efficacy of these treatments due to inherent concerns regarding immunosuppression, infection, and malignancy. We present the case of a patient who was safely treated with vedolizumab and ocrelizumab. The combination of biologics may be a safe and effective treatment for immune-mediated diseases.
Publish Date	2022-03-11 00:39
Citation	Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576
URL	https://www.wjgnet.com/2307-8960/full/v10/i8/2569.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i8.2569

Full Article (PDF)	WJCC-10-2569.pdf
Full Article (Word)	WJCC-10-2569.docx
Manuscript File	71264_Auto_Edited.docx
Answering Reviewers	71264-Answering reviewers.pdf
Audio Core Tip	71264-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	71264-Conflict-of-interest statement.pdf
Copyright License Agreement	71264-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	71264-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	71264-Language certificate.pdf
Peer-review Report	71264-Peer-review(s).pdf
Scientific Misconduct Check	71264-Bing-Fan JR-2.png
Scientific Editor Work List	71264-Scientific editor work list.pdf